Concepedia

Bruce W. Konicek

BW

20

Publications

3K

Citations

20

H-Index

1993

Active since

Affiliations

Eli Lilly (United States)(Current)

McGill University

Bruce W. Konicek is an author at Eli Lilly (United States) specializing in medicine, cell biology, and tumor biology.

ORCID

Top concepts

Publications per year

1993–2018

20

Publications

20

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

Jeremy R. Graff, Ann M. McNulty, Kimberly R. Hanna et al. · Cancer Research · 2005 · 435 citations · Full text

Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression

Jeremy R. Graff, Bruce W. Konicek, Ann M. McNulty et al. · Journal of Biological Chemistry · 2000 · 380 citations · Full text

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

Jeremy R. Graff, Bruce W. Konicek, Thomas M. Vincent et al. · Journal of Clinical Investigation · 2007 · 375 citations · Full text

, , +12

Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes

Christos G. Gkogkas, Arkady Khoutorsky, Ruifeng Cao et al. · Cell Reports · 2014 · 198 citations · Full text

eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival

Jeremy R. Graff, Bruce W. Konicek, Rebecca L. Lynch et al. · Cancer Research · 2009 · 197 citations

, , +11

Rows per page

1–5 of 20